4D Molecular Therapeutics (FDMT) FY Earnings Call Presentation

4DMT's Pipeline and Financial Status - 4DMT is officially a Phase 3 company[6] - 4DMT had $505 million cash as of December 31, 2024, providing runway into 2028[57] - 4DMT's pipeline is focused on large market indications with high unmet need[56] 4D-150 for Wet AMD - 4D-150 is a Phase 3 therapeutic designed to disrupt the global market for retinal vascular diseases and improve patient outcomes[8, 10, 18, 27, 37, 43] - The global market for retinal vascular diseases is $17 billion+ and growing[9, 11, 19, 28, 39, 45] - Topline data from wet AMD pivotal trials in the 4FRONT global registration program are expected in H2 2027[9, 11, 19, 28, 40, 45] - 4D-150 demonstrated transformative treatment burden reduction, with a projected 83% to 94% reduction in mean annual injections post 4D-150 in Phase 1/2a and Phase 2b populations[26] - In a Wet AMD population, 2.8% of patients experienced treatment-related 1+ vitreous cells at a single timepoint[32] 4D-150 for DME - In DME patients, there was no intraocular inflammation at any timepoint at any dose level[33] Market Dynamics - The total branded anti-VEGF market continues to grow, driven by incremental durability improvements, with aflibercept remaining the market leader[12] - The anti-VEGF market is expected to reach $17.1 million[14]